❌

Normal view

Received β€” 13 April 2026 ⏭ (Multiomics OR Omics) AND (Pancreatic)

Metformin suppresses Ξ²-cell apoptosis under ER stress by inhibiting protein translation

Metabolism. 2026 Apr 8:156607. doi: 10.1016/j.metabol.2026.156607. Online ahead of print.

ABSTRACT

Endoplasmic reticulum (ER) stress is a critical driver of pancreatic Ξ²-cell dysfunction and apoptosis. Although metformin, a drug used to treat type 2 diabetes, primarily decreases blood glucose levels by improving insulin sensitivity, its direct effects on Ξ²-cell survival remain unclear. Here, we investigated the effect of metformin on Ξ²-cell stress responses under ER stress conditions. Thapsigargin (Tg)-induced ER stress increased Ξ²-cell apoptosis in mouse islets, which was prevented by metformin in a dose-dependent manner. Treatment with metformin for 24 h suppressed the Tg-induced upregulation of unfolded protein response (UPR)-related genes, as confirmed by transcriptomic and pathway analyses. Quantitative proteomics revealed that Tg inhibited eIF2 signaling and protein translation, both of which were partially restored by metformin. Enrichment analysis further indicated the attenuation of apoptotic pathways in metformin-treated islets. Polysome profiling and puromycin incorporation assays demonstrated that metformin reduced protein translation independently of ER stress. Metformin promoted the dephosphorylation of 4E-BP1, a key initiator of cap-dependent protein translation that is activated by phosphorylation, and the antiapoptotic effect of metformin was abolished by 4E-BP1 knockdown in MIN6 cells. Phosphoproteomic analysis indicated that the activation of mTOR signaling, a kinase of 4E-BP1, in Tg-treated islets was mitigated by metformin. Taken together, these findings reveal a cytoprotective mechanism of metformin in Ξ²-cells, in which metformin suppresses ER stress-induced apoptosis through 4E-BP1-mediated inhibition of mRNA translation and modulation of mTOR signaling. This study highlights a Ξ²-cell-intrinsic action of metformin that may contribute to its long-term therapeutic benefits in diabetes management.

PMID:41962652 | DOI:10.1016/j.metabol.2026.156607

❌